

## Special Issue

# Osteoporosis Treatment: Targeting Osteoclast and Osteoblast Function with microRNA Therapeutics

### Message from the Guest Editor

Osteoporosis is a common age-related disorder characterized by decreased bone mass and structural deterioration, leading to a heightened risk of fractures. The current treatment options, including bisphosphonates and anti-RANK antibodies, target OCs in order to inhibit bone resorption but are limited by side effects and their inability to fully reverse the disease. Parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) therapies, which enhance OB function, but are hindered by high costs, frequent injection requirements, and a potential risk for osteosarcoma. Anti-sclerostin (SOST) antibodies promote OB differentiation but are also associated with adverse side effects and diminishing effectiveness over time. Thus, there is still a critical need for safe, effective, and durable therapies for osteoporosis. MicroRNAs (miRNAs) represent a promising class of disease-modifying agents for osteoporosis therapy, however, the clinical application of miRNAs must overcome several challenges. Addressing these obstacles will be essential in developing miRNAs as viable therapeutic agents for osteoporosis.

### Guest Editor

Dr. Aijaz Ahmad John Bhat

Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA

### Deadline for manuscript submissions

28 February 2026



## Cells

an Open Access Journal  
by MDPI

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/217755](https://mdpi.com/si/217755)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).